• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • Consumer Info
  • Guideline Notes
  • Medicine and Media
  • Pharmacogenomics
  • Visit My Etsy Store

Digital PharmD

Informatics in Pharmacy

Atrial Fibrillation

August 12, 2018 By Dr. G, PharmD

Print Friendly, PDF & Email

CHA2DS2-VasC Scoring

CHF or LVEF <40%

 Points
HTN1
Age >=752
Diabetes1
Stroke, TIA, thromboembolism2
Vascular Disease1
Age 65-74 years1
Sex female1

If score is:

  • 0 – Don’t need ASA or oral anticoagulant (OAC)
  • 1 – ASA
  • 2+ – OAC

CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk (another way to remember)

  • Congestive heart failure : + 1
  • Hypertension: + 1
  • Age >= 75: +2
  • Diabetes: +1
  • Stroke or thromboembolism: +2
  • Vascular disease: +1
  • Age 65-74: + 1
  • Sex Category Female: +1

Is score is 1 – ASA only, if 2 use another agent as follows:

  • DabigaTran (Pradaxa): 150 mg BID except in CrCl 30-50 or with dronedarone or ketoconazole, liver disease.  Idarucizumab is a reversal agent.  T – direct Thrombin inhibitor.
  • RivaroXAban (Xarelto) – higher risk of bleeding, 20 mg daily, reduce in renal disease, Xa inhibitor
  • ApiXAban (Eliquis) – 5 mg daily, reduce in renal disease. Xa inhibitor
  • Warfarin – more effective than clopidogrel and ASA, but less effective than above and more monitoring.

Drugs for Afib (see antiarrhythmics for more info)

  • Both the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) and Rate Control vs. Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) studies found no differences in survival between rate control and rhythm control in terms of mortality or morbidity.
  • Rate control:
    • esmolol, metoprolol, diltiazem, verapamil
    • With accessory pathway: amiodarone only
    • With heart failure: digoxin only
    • Goal is resting rate of <90
  • Pharmacological Conversion/Rhythm Control
    • dofetilide, flecainide, ibutilide, propafenone, amiodarone can be used as pharmacological conversion in afib.
    • flecainide, propafenone, and sotalol are recommended as first-line therapies in patients with lone AF
    • hypertensive patients with left ventricular hypertrophy are at an increased risk of torsades de pointes, propafenone and flecainide are suitable choices in the absence of ischemia.
    • in patients with cardiovascular disease without heart failure, sotalol is the first-line recommendation
    • in patients with cardiovascular disease with heart failure, amiodarone is the preferred choice, with dofetilide as a reasonable second-line alternative.

Anticoagulation in afib

  • For cardioversion:
    • If stable afib: be therapeutic on warfarin for 3 weeks (which means at goal INR for 3 weeks) before and 4 weeks after cardioversion
    • If unstable or they’ve been in afib less than 48 hours, convert and then continue for 4 weeks, INR 2-3 or initiate dabigatran, rivaroxaban or apixaban
    • TEE Guided conversion > 48 h = LMWH or UFH at the time of TEE, perform and if no thrombus seen, 4 weeks afterward.

Filed Under: Cardiology, Guideline Materials and Tips Tagged With: arrhythmia, CHA2DS2-VasC

Primary Sidebar

Newsletter

More to See

What You Need to Know About the 2022 Avian Influenza Outbreak

March 20, 2022 By Dr. G, PharmD

Endocarditis Guideline Review

February 24, 2022 By Dr. G, PharmD

Sinus Troubles: When Should I See My Doctor

January 5, 2022 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Smoking
  • What You Need to Know About the 2022 Avian Influenza Outbreak
  • Endocarditis Guideline Review
  • Sinus Troubles: When Should I See My Doctor
  • Common Pharmacogenomic SNPs and Interactions

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020